Country: Canada
Language: English
Source: Health Canada
KETOROLAC TROMETHAMINE
JUNO PHARMACEUTICALS CORP.
M01AB15
KETOROLAC
30MG
SOLUTION
KETOROLAC TROMETHAMINE 30MG
INTRAMUSCULAR
10X1ML
Prescription
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Active ingredient group (AIG) number: 0121995002; AHFS:
APPROVED
2015-07-10
Ketorolac Tromethamine Injection, USP Page 1 of 47 PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR KETOROLAC TROMETHAMINE INJECTION, USP Ketorolac Tromethamine Injection Solution, 30 mg/mL, Intramuscular USP Non-Steroidal Anti-Inflammatory Drug (NSAID) Juno Pharmaceuticals Corp. 402-2233 Argentia Road Mississauga, ON L5N 2X7 Date of Initial Authorization: July 10, 2015 Date of Revision: October 10, 2023 Submission Control Number: 274319 Ketorolac Tromethamine Injection, USP Page 2 of 47 RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 10/2023 7 WARNING AND PRECAUTIONS, Skin 10/2023 7 WARNING AND PRECAUTIONS, 7.1.1 Pregnant Women 10/2023 7 WARNING AND PRECAUTIONS, Monitoring and Laboratory Tests 10/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED . RECENT MAJOR LABEL CHANGES ................................................................................................... 2 TABLE OF CONTENTS ..................................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ............................................................................. 4 1 INDICATIONS ....................................................................................................................... 4 1.1 Pediatrics ....................................................................................................................... 4 1.2 Geriatrics ....................................................................................................................... 4 2 CONTRAINDICATIONS .......................................................................................................... 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ..................................................................... 6 4 DOSAGE AND ADMINISTRATION .......................................................................................... 7 4.1 Dosing Considerations ......... Read the complete document